Ordering workflow
EMR to pharmacy: how compounded prescriptions transmit
What decides whether an order can move through your prescribing system is whether it is a prescription at all. An order compounded for an identified individual patient is a prescription and travels as one. An order for stock names no patient, so it has nothing to transmit against — Georgia’s rules direct that such an order be placed "in the same manner as ordering products from a wholesale pharmaceutical distributor... and not by using a prescription drug order."
Can a compounded prescription go through your EMR?
If it is a prescription, yes — it is a prescription that happens to be for a compounded preparation.
There is no separate federal category for "compounded prescriptions" that excludes them from prescribing systems. Section 353a is written around "the receipt of a valid prescription order" for an identified individual patient; a prescription meeting that description is an ordinary prescription in every respect that matters to transmission.
What people are usually asking, underneath the question, is something else: whether the thing they want can travel that way. Often it cannot, and the reason has nothing to do with software.
What makes it a prescription rather than a stock order?
A named patient. That is the entire test, and it is federal.
Section 353a's exemption attaches where the drug is "compounded for an identified individual patient based on the receipt of a valid prescription order." Remove the identified patient and the exemption does not attach — and, for transmission purposes, there is no patient record for the order to belong to.
Georgia's rules make the operational consequence explicit. In the one channel where Georgia permits non-patient-specific supply, the recipient orders "in the same manner as ordering products from a wholesale pharmaceutical distributor... and not by using a prescription drug order." A stock order is a purchase. It goes through purchasing.
| Names an identified individual patient | Can move as a prescription | How it is placed | |
|---|---|---|---|
| Prescription for a named patient | Yes | Yes | Through the prescribing system, like any other prescription |
| The same prescription, delivered to your office for administration | Yes | Yes | Unchanged — the delivery address does not alter the transaction |
| Stock held for future patients | No | No — there is no patient record for it to belong to | As a purchase, "not by using a prescription drug order" |
Does delivering to your office change the answer?
No. The destination does not convert a prescription into stock, or stock into a prescription.
Illinois states this cleanly while drawing a boundary it needed to draw for other reasons: even where its rules prohibit sterile office use, "a sterile compounded drug may be delivered to the prescribing practitioner's office for administration pursuant to a valid patient-specific prescription." The preparation is dispensed against a named patient's order and then delivered somewhere convenient. It is still that patient's medication.
This is the single most useful distinction for a practice that wants product on site. Patient-specific fulfilment delivered to the practice is a different transaction from stock, not a lighter version of it — the two are compared at office stock and patient-specific fulfilment compared.
Does it matter which state the patient is in?
Yes, and some states attach their requirement to the shipment expressly rather than leaving it to inference.
Colorado provides that nonresident outlets registered there "may dispense compounded products and ship them into Colorado only pursuant to valid, patient-specific prescription orders." New York's registration regime reaches an out-of-state establishment that "ships, mails or delivers prescription drugs or devices to other establishments, authorized prescribers and/or patients residing in this state," and binds it to New York's own provisions for anything delivered in.
So a prescription that transmits cleanly is not automatically a prescription that may be filled from where your pharmacy sits. Which credential has to exist on the receiving end is set out at multi-state practice ordering: what changes per state.
Can a platform make the copy-rule determination for you?
No — and this is the place where automation most often oversteps.
Where a compounded preparation would otherwise be essentially a copy of a commercially available product, FDA's stated test carries an exception: it does not apply where "a prescriber determines and documents the compounded drug product contains a change that produces a significant difference from the commercially available drug product for an identified individual patient." Three features of that sentence do the work. The determination is the prescriber's, it is documented rather than assumed, and it is made for a named patient rather than adopted as a formulary position.
A pick-list of pre-written reasons attached to a product does not satisfy any of the three. Neither does a standing protocol. If a system offers the determination as a dropdown, what it has automated is the appearance of one.
Is platform-originated prescribing treated differently anywhere?
Arizona has written a rule aimed squarely at it, and the date is close.
From 5 September 2026, Arizona's amended compounding rules bar filling copy prescriptions submitted "through a pharmacy platform or electronic system" without patient-specific clinical information. The provision is part of the same rulemaking — published at 32 A.A.R. 1648, Register vol. 32 issue 30, 24 July 2026 — that closes Arizona's human office-use channel on the same date.
It is one state, and it is worth reading rather than generalising from. But it is a live example of a board regulating the origin of a prescription rather than its content, which is a distinction telehealth-shaped practices should expect to see again.
What this page deliberately does not describe
The plumbing.
Routing directories, message standards, network intermediaries and vendor implementations were not researched from primary sources, so none of them appears here and none should be inferred. Anyone who tells you a particular network "supports compounded prescriptions" is making a product claim, and the question to put back to them is which of the two transactions above they mean.
What decides your answer is upstream of all of it: whether the order names a patient. The rest of the workflow that follows from that is at how clinics order compounded medications, and the two pathways themselves at 503A pharmacies and 503B outsourcing facilities compared.
If you would rather have your intended orders sorted into the two transactions before you configure anything, you can apply for an account.